ArticleInternational journal of surgery (London, England)2026
Tumor stage and treatment outcomes in external auditory canal SCC: a multicenter cohort study.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExternal auditory canal squamous cell carcinoma (EAC SCC) is a rare malignancy with limited evidence guiding treatment strategies. This study sought to evaluate prognostic factors for overall survival (OS), cancer-specific survival (CSS), and time to progression (TTP), and to explore potential differences in outcomes between surgery-based and (chemo)radiotherapy [(C)RT]-based therapies.
methodsThis retrospective multicenter cohort study included 87 patients with histologically confirmed EAC SCC diagnosed between 2007 and 2022 at tertiary hospitals in Taiwan. Patients were grouped by treatment: (1) surgery plus adjuvant (C)RT; (2) (C)RT alone or (C)RT followed by salvage surgery. OS, CSS, and TTP were analyzed using Kaplan-Meier methods, Cox proportional hazards models, and inverse probability of treatment weighting (IPTW). Subgroup analyses were performed to explore treatment-effect modification by age, sex, and tumor stage.
resultsThe median age was 66 years, and 64.4% were male. The 5-year OS rate was 46%, with a median follow-up of 2.66 years. T4 tumors (HR 4.98, 95% CI: 1.71-14.5), nodal (HR 3.59, 95% CI: 1.58-8.18), and distant metastasis (HR 2.92, 95% CI: 1.14-7.49) were associated with worse OS, though only tumor stage remained significant after adjustment. Patients treated with (C)RT-based treatment showed poorer OS compared with surgery plus adjuvant (C)RT in crude and IPTW analyses, but these associations attenuated in fully adjusted models. Subgroup analyses suggested that outcome differences were more apparent in older patients, males, and those with advanced tumors although residual confounding effect and the small sample may have influenced these findings.
conclusionsTumor stage and treatment modality appeared to be important prognostic factors in this cohort of EAC SCC. While surgery combined with adjuvant (C)RT was associated with more favorable outcomes in several analyses, the observational design limited causal inference. These results should be viewed as hypothesis-generating and underscore the need for larger prospective studies with standardized treatment reporting to clarify optimal strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.